Skip to main content

Ascendis Pharma A

corporate_fare Company Profile

Ascendis Pharma A

ASND·NASDAQ·Life Sciences·CIK 0001612042

Ascendis Pharma A/S is a biopharmaceutical company that develops TransCon-based therapies for medical needs in Europe, the United States, and internationally. The company offers SKYTROFA, which treats pediatric patients with growth hormone deficiency. It also provides YORVIPATH, a once-daily subcutaneous injection for adults with chronic hypoparathyroidism. Ascendis Pharma A/S is developing a pipeline of three independent endocrinology rare disease product candidates that are in clinical development. Additionally, the company focuses on advancing oncology therapeutic candidates. It was incorporated in 2006 and is based in Hellerup, Denmark.

Ascendis Pharma A (NASDAQ:ASND) is a publicly traded company in the Life Sciences sector. Wiseek monitors ASND SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • TransCon PTH Shows Sustained Efficacy, Safety Through 3.5 Years in Phase 3 Hypoparathyroidism Trial
  • Long-Term Data: TransCon PTH Sustains Efficacy for 5 Years in Hypoparathyroidism
  • EVP Sells All Direct Holdings for $4.6M Amidst Positive Company News
  • Ascendis Pharma Reports Strong Q1 Profit & $187.5M PRV Sale; Redeems $575M Convertible Notes
  • Pivotal Trial Shows TransCon CNP Delivers Sustained 2-Year Growth Gains in Achondroplasia

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
€720.13M EUR
Net Income
-€228.03M EUR
Diluted EPS
-€3.76 EUR
Op. Cash Flow
€53.9M EUR
Gross Profit
€625.22M EUR
Operating Income
-€136.27M EUR
Cash & Equivalents
€616.04M EUR
Total Debt
€385.25M EUR
Debt / Equity
-2.37×
Net Margin
-31.7%
Shares Outstanding
61.98M sh
Source: 20-F · filed 2026-02-11 · accession 0001193125-26-046590

Insider Transactions

ASND files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →
$218.06
52-week range · as of 2026-05-12 $150.89 – $250.74
Market cap
$13.6B
Volume
405K (0.7× avg)
3-mo avg 594.5K
Live data · 2026-06-14 05:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ASND - Latest Insights

ASND
Jun 13, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $218.06
Real-time Price: $218.06 info
Change: $0 (0%) info
Market Cap: $13.602B info
ASND
Jun 11, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $215.60
Real-time Price: $218.06 info
Change: +$2.46 (+1%) info
Market Cap: $13.602B info
ASND
May 12, 2026, 4:08 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $237.65
Real-time Price: $218.06 info
Change: -$19.59 (-8%) info
Market Cap: $13.602B info
ASND
May 07, 2026, 7:45 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $227.02
Real-time Price: $218.06 info
Change: -$8.96 (-4%) info
Market Cap: $13.602B info
ASND
May 06, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $235.90
Real-time Price: $218.06 info
Change: -$17.84 (-8%) info
Market Cap: $13.602B info
ASND
Apr 21, 2026, 5:16 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $240.00
Real-time Price: $218.06 info
Change: -$21.94 (-9%) info
Market Cap: $13.602B info
ASND
Apr 20, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $244.48
Real-time Price: $218.06 info
Change: -$26.42 (-11%) info
Market Cap: $13.602B info
ASND
Apr 08, 2026, 4:02 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $233.95
Real-time Price: $218.06 info
Change: -$15.89 (-7%) info
Market Cap: $13.602B info
ASND
Apr 08, 2026, 8:01 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $226.96
Real-time Price: $218.06 info
Change: -$8.90 (-4%) info
Market Cap: $13.602B info
ASND
Apr 07, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $228.00
Real-time Price: $218.06 info
Change: -$9.94 (-4%) info
Market Cap: $13.602B info
ASND
Apr 06, 2026, 4:13 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $228.00
Real-time Price: $218.06 info
Change: -$9.94 (-4%) info
Market Cap: $13.602B info
ASND
Mar 17, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $228.06
Real-time Price: $218.06 info
Change: -$10.00 (-4%) info
Market Cap: $13.602B info
ASND
Mar 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $231.12
Real-time Price: $218.06 info
Change: -$13.06 (-6%) info
Market Cap: $13.602B info
ASND
Mar 16, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $231.03
Real-time Price: $218.06 info
Change: -$12.97 (-6%) info
Market Cap: $13.602B info
ASND
Mar 16, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $229.01
Real-time Price: $218.06 info
Change: -$10.95 (-5%) info
Market Cap: $13.602B info
ASND
Mar 05, 2026, 5:04 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $237.29
Real-time Price: $218.06 info
Change: -$19.23 (-8%) info
Market Cap: $13.602B info
ASND
Mar 02, 2026, 6:05 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $241.00
Real-time Price: $218.06 info
Change: -$22.94 (-10%) info
Market Cap: $13.602B info
ASND
Feb 27, 2026, 6:01 PM EST
Source: Reuters
Importance Score:
9
Price at Filing: $233.50
Real-time Price: $218.06 info
Change: -$15.44 (-7%) info
Market Cap: $13.602B info
ASND
Feb 23, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $234.95
Real-time Price: $218.06 info
Change: -$16.89 (-7%) info
Market Cap: $13.602B info
ASND
Feb 11, 2026, 4:50 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $221.00
Real-time Price: $218.06 info
Change: -$2.94 (-1%) info
Market Cap: $13.602B info